A biotech with a 0.54M float just gapped 101% on ASCO cancer data. A Chinese brokerage just lost 39% overnight after regulators opened case filings against it. And IBM collected a $1 billion government check to build quantum chips. Three completely different stories, all moving the tape before the open on May 22.
Market News -- May 22, 2026
The dominant macro story this morning is a broad China ADR selloff triggered by a regulatory crackdown on offshore brokerages. China's securities regulator opened formal case filings against Futu Holdings for operating brokerage services in mainland China without an onshore license, with asset confiscation proceedings initiated and a two-year wind-down window imposed. FUTU is down 39% premarket. The contagion is spreading across the entire China ADR complex -- BABA, PDD, JD, LI, XPEV, BILI, and VNET are all down 2% to 6% in sympathy as traders reprice regulatory risk.
The second major theme is quantum continuation. The US government announced a $2 billion investment program in nine quantum computing companies in exchange for equity stakes on May 21. IBM received $1 billion toward a dedicated quantum chip manufacturing facility. IBM is up 12% and extending Thursday's move. Quantum names INFQ, RGTI, and OKLO are all gapping higher. IONQ is the notable exception, fading 2.4% as it digests yesterday's surge.
On the low float side, Akari Therapeutics (AKTX) is up over 100% on preclinical data released in connection with the ASCO Annual Meeting 2026, reporting synergistic tumor-killing activity for AKTX-101 with KRAS inhibitors in pancreatic cancer models. GeoVax Labs (GOVX) is up 31% with a 0.96M float, continuing its multi-day momentum run on Ebola vaccine development news.
Economic Calendar -- Week of May 18, 2026
Friday May 22: No high-impact scheduled economic releases. Pre-Memorial Day weekend session. Historically lower volume in the afternoon as institutional desks reduce exposure. Morning volatility at the open tends to be sharper on low-volume Fridays.
Key data from the week: FOMC Minutes (Wed) showed Fed holding rate path -- no cuts signaled. Initial Jobless Claims (Thu) came in as expected. NVDA earnings beat drove the semiconductor complex higher all week.
Gap Up Watch -- May 22, 2026
AKTX -- +100.99% -- Float: 0.54M -- Price: $10.13
Akari Therapeutics released preclinical data in connection with the ASCO Annual Meeting 2026 showing AKTX-101 delivered synergistic cytotoxic activity with KRAS inhibitors in pancreatic cancer models. The data suggests combination potential beyond the company's current Phase 1 plan. With a 0.54M float and a market cap under $10M, this is a classic low-float binary catalyst runner. Volume at 8:18 AM was 7.18M -- already 13x the entire float has traded in premarket alone.
GOVX -- +30.69% -- Float: 0.96M -- Price: $3.60
GeoVax Labs has been in a multi-day momentum run since mid-May, driven by analyst coverage noting the company is among the few developing an Ebola vaccine, alongside a $3 million private placement financing. With a 0.96M float and 12.37M premarket volume -- approximately 13x the float -- this is a momentum and float-driven move. The key level is whether it holds the prior day close or fades into the open.
FUTU -- -39.33% -- Float: 90.42M -- Price: $75.14 (Gap Down -- Leading Story)
China's securities regulator initiated formal case filings against Futu Holdings for operating brokerage services in mainland China without an onshore license, with asset confiscation proceedings and a mandatory two-year wind-down of mainland operations. FUTU's growth model has been built on serving mainland Chinese retail investors. This ruling directly threatens that revenue base. The stock is down 39% premarket on 13.08M shares of volume.
The full watch list continues below for Premium members. Remaining gap ups: INFQ, EOSE, RKLB, NOK, OKLO, RGTI, IBM. Full gap down list: FRGT, AIIO, VNET, PDD, ONCO, LI, BABA, BILI, JD, ARM, IONQ, XPEV. Trader's note on the China ADR setup and the low-float runner framework for today's open.
Subscribe to Default to read the rest.
Become a paying subscriber of Default to get access to this post and other subscriber-only content.
Upgrade